Traders should monitor for any default escalation, asset seizure risk, or failure to resolve the Decathlon Alpha IV dispute, which could trigger bankruptcy proceedings. The Nistico consulting arrangement raises governance concerns given his prior CEO role and the speculative vesting condition, potentially signaling internal instability or a strategic pivot attempt.
Price Chart
Executive Summary
Splash Beverage Group disclosed multiple distress signals: it amended settlement agreements to extend $535,595 in payments to former investors, faced a $2.83M loan default demand from Decathlon Alpha IV, and saw two board members resign. One, Robert Nistico, transitioned to a paid consultant with stock options tied to an acquisition of Medterra CBD, LLC. The combination of liquidity pressure, governance changes, and disputed debt obligations points to significant financial and operational stress.
Key Facts
- Company extended $535,595 in settlement payments to former investors to June 1, 2026, with 12% interest and attorney fees.
- Received a demand letter from Decathlon Alpha IV, L.P. for $2,833,395.98 in alleged loan defaults under a 2020 Revenue Loan and Security Agreement.
- Board members Justin Yorke and Robert Nistico resigned; Nistico was immediately hired as a consultant for $5,000/month and a stock option grant of 250,000 shares.
- Nistico's stock options vest only if the company acquires Medterra CBD, LLC, introducing speculative incentive structure.
- Company disputes the loan default and has initiated discussions with the lender but faces secured creditor claims on all company and subsidiary assets.
Financial Impact
Approximately $3.37 million in near-term financial obligations ($535,595 in settlements + $2.83M loan demand), both disputed but creating liquidity risk. Additional $31,000 in expenses and $30,000 in consulting fees committed to Nistico.
Risk Factors
- Risk of loan default leading to asset seizure, given the security interest held by Decathlon Alpha IV.
- Further board or management departures could destabilize the company.
- Potential for additional litigation from other investors or creditors given the pattern of disputes.
- Dilution risk from the 250,000-share option grant if the Medterra CBD acquisition occurs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-000612 |
| Document: 0001731122-26-000612-index-headers.html | 0001731122-26-000612 |
| Document: 0001731122-26-000612-index.html | 0001731122-26-000612 |
| Document: 0001731122-26-000612.txt | 0001731122-26-000612 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 8-K | $0.001100 | awaiting T+20 | — | — |
May 15, 2026 23w ago | 8-K | $0.002100 | awaiting T+20 | — | — |
May 5, 2026 25w ago | 8-K | — | awaiting T+20 | — | — |
Apr 27, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 24, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers